Evercore ISI Group Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $115
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Cory Kasimov maintains an Outperform rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and raises the price target from $113 to $115.
August 06, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evercore ISI Group analyst Cory Kasimov maintains an Outperform rating on Biomarin Pharmaceutical and raises the price target from $113 to $115.
The maintained Outperform rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100